ArticleNPJ digital medicine2022
Developing machine learning algorithms for dynamic estimation of progression during active surveillance for prostate cancer.
Article in NPJ digital medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Artificial Intelligence (AI)-based tools in the diagnosis and management of prostate cancer: a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2026Pooled it
- Prediction models in prostate cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Predictive models for biopsy upgrading in active surveillance for prostate cancer: a scoping review.World journal of urology · 2026Article
- Personalized risk-adapted models in prostate cancer during active surveillance using MRI-a narrative review.European radiology · 2025Review
- Personalized Biopsy Schedules Using an Interval-Censored Cause-Specific Joint Model.Statistics in medicine · 2025Article
- The 5-year results of the Stratified Cancer Active Surveillance programme for men with prostate cancer.BJU international · 2025Article
- Survival path model outperforms conventional static machine learning models in long-term dynamic prognosis prediction for patients with intermediate stage hepatocellular carcinoma.Bioinformatics advances · 2025Article
- Seeing the random forest through the decision trees. Supporting learning health systems from histopathology with machine learning models: Challenges and opportunities.Journal of pathology informatics · 2024Review
- A radiogenomic clinical decision support system to inform individualized treatment in advanced nasopharyngeal carcinoma.iScience · 2024Article
- Machine Learning for Dynamic Prognostication of Patients With Hepatocellular Carcinoma Using Time-Series Data: Survival Path Versus Dynamic-DeepHit HCC Model.Cancer informatics · 2024Article
- Bridging the Worlds of Pharmacometrics and Machine Learning.Clinical pharmacokinetics · 2023Review
- Machine Learning Models for ASCVD Risk Prediction in an Asian Population - How to Validate the Model is Important.Acta Cardiologica Sinica · 2023Article
- Comparing Active Surveillance and Watchful Waiting With Radical Treatment Using Machine Learning Models Among Patients With Prostate Cancer.JCO clinical cancer informatics · 2023Article
- Comparison of MRI radiomics-based machine learning survival models in predicting prognosis of glioblastoma multiforme.Frontiers in medicine · 2023Article
- Development and validation of machine learning models to predict survival of patients with resected stage-III NSCLC.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Active Surveillance (AS) for prostate cancer is a management option that continually monitors early disease and considers intervention if progression occurs. A robust method to incorporate "live" updates of progression risk during follow-up has hitherto been lacking. To address this, we developed a deep learning-based individualised longitudinal survival model using Dynamic-DeepHit-Lite (DDHL) that learns data-driven distribution of time-to-event outcomes. Further refining outputs, we used a reinforcement learning approach (Actor-Critic) for temporal predictive clustering (AC-TPC) to discover groups with similar time-to-event outcomes to support clinical utility. We applied these methods to data from 585 men on AS with longitudinal and comprehensive follow-up (median 4.4 years). Time-dependent C-indices and Brier scores were calculated and compared to Cox regression and landmarking methods. Both Cox and DDHL models including only baseline variables showed comparable C-indices but the DDHL model performance improved with additional follow-up data. With 3 years of data collection and 3 years follow-up the DDHL model had a C-index of 0.79 (±0.11) compared to 0.70 (±0.15) for landmarking Cox and 0.67 (±0.09) for baseline Cox only. Model calibration was good across all models tested. The AC-TPC method further discovered 4 distinct outcome-related temporal clusters with distinct progression trajectories. Those in the lowest risk cluster had negligible progression risk while those in the highest cluster had a 50% risk of progression by 5 years. In summary, we report a novel machine learning approach to inform personalised follow-up during active surveillance which improves predictive power with increasing data input over time.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.